Lilly sees surging sales in contrast to obesity rival Novo

Core Viewpoint - Eli Lilly & Co. has provided a positive sales forecast for the year, driven by strong demand for its weight loss drug, positioning it favorably in the obesity market compared to rival Novo Nordisk, which anticipates a sales decline due to price competition [1][3]. Sales Forecast and Market Position - Lilly expects full-year sales to reach between $80 billion and $83 billion, surpassing Wall Street's average estimate of $77.7 billion [3] - The company anticipates a sales growth of up to 27% this year, contrasting with Novo Nordisk's warning of a potential 13% sales drop [1][3]. Competitive Landscape - Lilly's Mounjaro and Zepbound drugs have a decade of patent life remaining, giving it a competitive edge over Novo, whose drugs may face generic competition soon [3] - Lilly's Zepbound has shown to be more effective than Novo's Wegovy, with patients losing about two inches more off their waists in head-to-head studies [10]. Product Developments - Lilly is preparing to launch a new multidose version of Zepbound, which will be available for Medicare patients once coverage is established [7][8]. - The company is also awaiting approval for its weight loss pill, expected as soon as April, with a projected cost of $149 per month for the lowest dose [6][5]. Financial Performance - In the fourth quarter, Lilly reported sales of $19.3 billion, exceeding analyst estimates of $18 billion, with Zepbound sales at $4.3 billion and Mounjaro at $7.4 billion [15]. - Lilly's earnings per share of $7.54 also surpassed expectations of $6.73 [15]. Future Prospects - Lilly is testing new weight-loss drugs, including retatrutide, which has shown promising results in trials, potentially making it the most effective weight-loss medicine [12]. - The company is expanding its research into other therapeutic areas, including neuroscience and cancer, with new drugs like Kisunla for Alzheimer's [14].